Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts

Archives of Gynecology and Obstetrics

Volumn 288, Issue 4, 2013, Pages 859-865

  Robati, Minoo ^a   Ghaderi, Abbas ^b   Mehraban, Mitra ^a   Shafizad, Amin ^c   Nasrolahi, Hamid ^c   Mohammadianpanah, Mohammad ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benign ovarian cysts; CA125; Epithelial ovarian cancer; Vascular endothelial growth factor (VEGF)

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; HUMAN; OVARY CARCINOMA; OVARY CYST; PELVIC DISEASE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84885388103     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2819-7     Document Type: Article

References (21)

1. Perez-Lopez FR, Chedraui P, Troyano-Luque JM (2010) Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. Gynecol Endocrinol 26(9):631-643. doi: 10.3109/09513590.2010.487611
2. Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S, Uzun H, Sanioglu C, Aydinli K, Kosebay D (2003) Vascular endothelial growth factor in adnexal masses. Int J Gynaecol Obstet 83(1):53-58
3. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H (2003) Histological classification of ovarian cancer. Med Electron Microsc 36(1):9-17. doi: 10.1007/s007950300002
4. Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J (2011) Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol 18(1):49-57. doi: 10.1245/s10434-010-1245-3
5. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
6. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189(4):1120-1127
7. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646. doi: 10.1126/science.1088759
8. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109(9):1887-1896. doi: 10.1002/cncr.22594
9. Moore RG, MacLaughlan S, Bast RC Jr (2010) Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 116(2):240-245. doi: 10.1016/j.ygyno.2009.09.041
10. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(Suppl 3):274-281. doi: 10.1111/j.1525-1438.2005.00441.x
11. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr (1992) Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80(1):14-18
12. Orre M, Rogers PA (1999) VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer 84(2):101-108
13. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML (2007) The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96(4):541-545. doi: 10.1038/sj.bjc.6603487
14. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC (2009) Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. Int J Gynecol Cancer 19(7):1214-1220. doi: 10.1111/IGC.0b013e3181a386e5
15. Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A (2010) Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 10(8):1069-1083. doi: 10.1586/erm.10.87
16. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46. doi: 10.1016/j.ygyno.2008.08.031
17. Kut C, Mac Gabhann F, Popel AS (2007) Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97(7):978-985. doi: 10.1038/sj.bjc.6603923
18. Tan X, Shen K, Liu D, Xu X, Lang J (2000) The diagnostic and prognostic values of assay of serum vascular endothelial growth factor in epithelial ovarian cancer. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae 22(4):352-355
19. Oehler MK, Caffier H (2000) Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 20(6D):5109-5112
20. Candido Dos Reis FJ, Moreira de Andrade J, Bighetti S (2002) CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest 54(3):132-136. doi: 67877
21. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK (2002) Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8(10):3193-3197